Galapagos receives ?7.4 M milestone in arthritis alliance with GlaxoSmithKline
(Thomson Reuters ONE) -
· Completed first-in-human trials for GLPG0555
· Alliance's second novel candidate drug, GLPG0778, enters clinic
Mechelen, Belgium; 11 January 2011 - Galapagos NV (Euronext: GLPG) announced
today progress achieved in its arthritis alliance with GlaxoSmithKline (GSK).
Galapagos completed first-in-human trials with GLPG0555 in healthy volunteers.
Galapagos also initiated clinical Phase I development for a second candidate
drug, GLPG0778, which triggered a milestone payment of ?7.4 million.
Initial Phase I results for the first candidate drug in the alliance, GLPG0555,
showed no changes in vital signs and laboratory parameters for dosing up to 14
consecutive days in healthy volunteers. GLPG0555 was well tolerated with no
severe adverse events reported.
In late December 2010, Galapagos initiated a first-in-human trial for GLPG0778,
which is being conducted in healthy volunteers over the coming months. This
second candidate drug, which inhibits kinase target GT623, has demonstrated
excellent activity and safety in biochemical and animal models, and has
successfully completed pre-clinical development.
"We are pleased to report progress on candidate drugs in our arthritis alliance
with GSK," said Onno van de Stolpe, CEO of Galapagos. "Today's announcement
increases our clinical rheumatoid arthritis portfolio to four candidate drugs,
with a balanced risk profile of known and novel modes of action."
Details of GLPG0555 Phase I clinical trials
The primary endpoints of the first-in-human trials were to determine the safety,
tolerability and PK profile of candidate drug GLPG0555. The double-blind,
single ascending and multiple dose studies were conducted in 35 healthy human
volunteers.
A double-blind, multiple ascending dose study for GLPG0555 is currently being
conducted in up to 40 healthy human volunteers to further assess the safety, PK
and biomarker profile. Furthermore, Galapagos is preparing to investigate a
novel capsule formulation for later stage trials.
Details of GLPG00778 first-in-human trial
The primary endpoints of the first-in-human trial for GLPG0778 will be to
determine the safety, tolerability and PK. The secondary endpoint will be to
explore biomarker effects of this candidate drug. The placebo-controlled,
double-blind, single ascending and multiple dose studies are being conducted in
40 healthy human volunteers in Belgium over the coming months.
About Galapagos' arthritis alliance with GlaxoSmithKline
GSK and Galapagos initiated an arthritis alliance to discover and develop
disease-modifying drugs for GSK's global R&D organization in June 2006. GSK and
Galapagos expanded the alliance on three occasions to include additional targets
and increase the number of programs. Following the latest expansion in December
2009, Galapagos is eligible to receive more than ?200 million in milestones,
plus up to double-digit royalties from GSK. GSK has an exclusive option to
further develop and commercialize these compounds on a worldwide basis. Since
the start of the arthritis alliance, Galapagos has received a total of ?54.7
million in payments from GSK.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with seven clinical and over 50 discovery
programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly,
Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to
receive up to ?3.3 billion in downstream milestones, plus royalties. The
Galapagos Group has over 800 employees and operates facilities in seven
countries, with global headquarters in Mechelen, Belgium. More info at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1478532]
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 50340
Anzahl Zeichen: 6353
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos receives ?7.4 M milestone in arthritis alliance with GlaxoSmithKline"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
